Leukemia, Acute Lymphoblastic disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LKM062 MIFTS: 69	Leukemia, Acute Lymphoblastic Categories: Rare diseases, Cancer diseases, Genetic diseases, Immune diseases, Blood diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Leukemia, Acute Lymphoblastic

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic ⁵⁷ ⁷⁵ ¹³ ¹³ ¹³ ¹³ ³⁸

Acute Lymphoblastic Leukemia ³⁸ ⁷⁶ ⁵³ ²⁹ ⁶

Leukemia, Acute Lymphoblastic, Susceptibility to ²⁹ ¹³ ⁶

All ⁵⁷ ⁵³ ⁷⁵

Leukemia, T-Cell Acute Lymphoblastic ¹³ ⁴⁰

Acute Lymphocytic Leukemia ⁵³ ⁷³

Leukemia, Acute Lymphoblastic, Susceptibility to, 3 ⁷³

Leukemia, Acute Lymphocytic, Susceptibility to, 1 ⁵⁷

Precursor Cell Lymphoblastic Leukemia Lymphoma ⁷³

Leukemia Acute Lymphoblastic B-Hyperdiploid ⁷⁵

Childhood Acute Lymphoblastic Leukemia ⁷⁵

Leukemia, Acute, Lymphoblastic, T-Cell ⁴⁰

Leukemia, Acute T-Cell Lymphoblastic ¹³

Leukemia B-Cell Acute Lymphoblastic ⁷⁵

Leukemia T-Cell Acute Lymphoblastic ⁷⁵

Leukemia, Acute Lymphoblastic, 3 ⁷⁵

Leukemia, Lymphocytic, Acute, L1 ⁷³

Leukemia Acute Lymphoblastic 1 ⁷⁵

Leukemia, Acute, Lymphoblastic ⁴⁰

Leukemia, Acute Lymphocytic 1 ⁵⁷

Leukemia Acute Lymphocytic 1 ⁷⁵

Lymphoblastic Leukemia Acute ⁵⁵

Leukemia, Acute Lymphocytic ¹³

Leukemia Acute Lymphocytic ⁷⁵

All3 ⁷⁵

All1 ⁷⁵

Characteristics:

HPO:

³²

leukemia, acute lymphoblastic:
Inheritance polygenic inheritance

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Lymphoid leukaemia

Acute lymphoblastic leukaemia [ALL]

External Ids:

OMIM ⁵⁷ 613065

MedGen ⁴² C1961102 C2751594 C2751595 more

MeSH ⁴⁴ D054198

ICD10 ³³ C91.0

SNOMED-CT via HPO ⁶⁹ 128822004 91857003

UMLS ⁷³ C1961102 C0023452 C3809874

Sources

Summaries for Leukemia, Acute Lymphoblastic

NIH Rare Diseases : ⁵³ Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes. Having one or more risk factors does not mean that a person definitely will develop ALL. Treatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells. Treatment options may involve systemic and/or intrathecal chemotherapy, radiation therapy, targeted therapy, and/or a stem cell transplant. Biologic therapy and chimeric antigen receptor (CAR) T-cell therapy are currently being studied as treatment options and may be used when other therapies are not working. The chance of recovery also depends on many factors. With treatment, about 98% of children with ALL go into remission, and 85% of those with first-time ALL are expected have no long-term complications. The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments.

MalaCards based summary : Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to leukemia, acute lymphoblastic 3 and acute leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia, Acute Lymphoblastic is ETV6 (ETS Variant 6), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Arranon and Blincyto have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotype is acute lymphoblastic leukemia.

OMIM : ⁵⁷ Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065)

UniProtKB/Swiss-Prot : ⁷⁵ Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes. Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Wikipedia : ⁷⁶ Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Sources

Related Diseases for Leukemia, Acute Lymphoblastic

Diseases in the Lymphoblastic Leukemia family:

Leukemia, Acute Lymphoblastic	Leukemia, Acute Lymphoblastic 2
Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)

#	Related Disease	Score	Top Affiliating Genes
1	leukemia, acute lymphoblastic 3	34.9	ETV6 FLT3 PAX5
2	acute leukemia	30.7	ETV6 FLT3 PAX5
3	leukemia, acute myeloid	29.1	ETV6 FLT3 MIR155 MIR199B MIR21 MIR210
4	acute lymphoblastic leukemia, childhood	12.5
5	b-cell childhood acute lymphoblastic leukemia	12.5
6	precursor t-cell acute lymphoblastic leukemia	12.3
7	leukemia, acute lymphoblastic 2	12.3
8	acute lymphoblastic leukemia congenital sporadic aniridia	12.1
9	acute t cell leukemia	11.8
10	lymphoblastic leukemia, acute, with lymphomatous features	11.5
11	acute lymphocytic leukemia	11.1
12	lymphoid leukemia	11.1	ETV6 FLT3 GNB1
13	ovarian serous carcinoma	10.9	MIR21 MIR23B MIR27A
14	neutrophilia, hereditary	10.9	FLT3 MIR223
15	mn1	10.9	ETV6 FLT3
16	muscular dystrophy, limb-girdle, type 2a	10.9	MIR221 MIR222 MIR223
17	lymphoma, hodgkin, classic	10.9	MIR155 MIR21 PAX5
18	leiomyoma, uterine	10.9	MIR203A MIR21 MIRLET7C
19	polymyositis	10.9	MIR155 MIR21 MIR210 MIR222
20	nonalcoholic fatty liver disease	10.9	MIR203A MIR22 MIR27A MIRLET7C
21	leukemia, chronic myeloid	10.8	ETV6 FLT3 MIR203A MIR223
22	kidney cancer	10.8	MIR21 MIR210 MIR27A
23	diffuse large b-cell lymphoma	10.8	MIR155 MIR21 MIR210 MIR221
24	pancreatic ductal adenocarcinoma	10.8	MIR155 MIR203A MIR21 MIR221 MIR223
25	inclusion body myositis	10.8	MIR155 MIR21 MIR221 MIR222 MIR223
26	facioscapulohumeral muscular dystrophy 1	10.8	MIR155 MIR199B MIR21 MIR221 MIR222
27	thyroid cancer, nonmedullary, 1	10.7	MIR155 MIR199B MIR21 MIR221 MIR222
28	squamous cell carcinoma, head and neck	10.7	MIR155 MIR21 MIR210 MIR22 MIR221
29	acute promyelocytic leukemia	10.7	FLT3 MIR210 MIR221 MIR223 MIRLET7C
30	ulcerative colitis	10.7	MIR203A MIR21 MIR23B
31	leukemia, chronic lymphocytic	10.7	MIR155 MIR21 MIR221 MIR223 MIR23B PAX5
32	glioblastoma multiforme	10.7	MIR155 MIR21 MIR210 MIR221
33	bone marrow cancer	10.6	ETV6 FLT3 MIR155
34	muscular dystrophy, duchenne type	10.6	MIR155 MIR199B MIR210 MIR22 MIR221 MIR222
35	acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)	10.6	ETV6 FLT3
36	dermatomyositis	10.6	MIR199B MIR21 MIR210 MIR221 MIR222 MIR223
37	glioma	10.6	MIR21 MIR210 MIR221 MIR222
38	bladder cancer	10.6	MIR203A MIR21 MIR221 MIR222 MIR223 MIR23B
39	melanoma	10.5	MIR199B MIR210 MIR221 MIR222 MIR23B MIR27A
40	gastric cancer	10.5	MIR203A MIR21 MIR221 MIR222 MIR223 MIR27A
41	lymphoblastic leukemia	10.5
42	leukemia	10.4
43	oral squamous cell carcinoma	10.4	MIR155 MIR199B MIR203A MIR21 MIR221 MIR223
44	ovarian cancer	10.4	MIR155 MIR21 MIR210 MIR221 MIR222 MIR223
45	pancreatic cancer	10.3	MIR155 MIR203A MIR21 MIR210 MIR221 MIR222
46	glioblastoma	10.0	MIR21 MIR221 MIR222 MIR23B
47	lung cancer	10.0	MIR155 MIR199B MIR203A MIR21 MIR210 MIR22
48	breast cancer	10.0	MIR152 MIR155 MIR199B MIR203A MIR21 MIR210
49	prostate cancer	9.9	MIR199B MIR203A MIR21 MIR210 MIR22 MIR221
50	hepatocellular carcinoma	9.8	MIR152 MIR155 MIR199B MIR203A MIR21 MIR22

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:

Sources

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

Clinical features from OMIM:

613065

Human phenotypes related to Leukemia, Acute Lymphoblastic:

³²

#	Description	HPO Frequency	HPO Source Accession
1	acute lymphoblastic leukemia ³²		HP:0006721

UMLS symptoms related to Leukemia, Acute Lymphoblastic:

angina pectoris, chest pain, edema

Sources

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

FDA approved drugs:

(show all 7)

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Arranon ¹⁸ ⁴⁹	NELARABINE	GlaxoSmithKline	October 2005
FDA Label: Arranon Disease/s that Drug Treats:Lymphoblastic Leukemia Indications and Usage: ¹⁸ ARRANON is a nucleoside metabolic inhibitor indicated for the treatment ofpatients with T-cell acute lymphoblastic leukemia and T-cell lymphoblasticlymphoma whose disease has not responded to or has relapsed followingtreatment with at least two chemotherapy regimens. This use is based on theinduction of complete responses. Randomized trials demonstrating increasedsurvival or other clinical benefit have not been conducted. (1) DrugBank Targets: ¹⁶ DNA Mechanism of Action: ¹⁸ Target: DNA synthesis Action: disruptor --> apoptosis FDA: Nelarabine is a pro-drug of the deoxyguanosine analogue 9-Î²-D-arabinofuranosylguanine266 (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by adenosine deaminase267 (ADA) to ara-G, mono-phosphorylated by deoxyguanosine kinase and deoxycytidine kinase, and268 subsequently converted to the active 5â-triphosphate, ara-GTP. Accumulation of ara-GTP in269 leukemic blasts allows for incorporation into deoxyribonucleic acid (DNA), leading to inhibition270 of DNA synthesis and cell death. Other mechanisms may contribute to the cytotoxic and271 systemic toxicity of nelarabine.
2	Blincyto ¹⁸ ⁴⁹	BLINATUMOMAB	Amgen	December 2014
FDA Label: Blincyto Disease/s that Drug Treats:Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia Indications and Usage: ¹⁸ BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated forthe treatment of Philadelphia chromosome-negative relapsed or refractory Bcellprecursor acute lymphoblastic leukemia (ALL). This indication isapproved under accelerated approval. Continued approval for this indicationmay be contingent upon verification of clinical benefit in subsequent trials. (1) DrugBank Targets: ¹⁶ 1. B-lymphocyte antigen CD19;2. T-cell surface glycoprotein CD3 delta chain Mechanism of Action: ¹⁸ Target: CD19-directed CD3 T-cell Action: engager FDA: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on thesurface of cells of B-lineage origin and CD3 expressed on the surface of T cells. It activates endogenousT cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant Bcells. Blinatumomab mediates the formation of a synapse between the T cell and the tumor cell,upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatorycytokines, and proliferation of T cells, which result in redirected lysis of CD19+ cells.
3	Clolar ¹⁸ ⁴⁹	CLOFARABINE	Genzyme	December, 2004
FDA Label: Clolar Disease/s that Drug Treats:Lymphoblastic Leukemia Indications and Usage: ¹⁸ Clolar (clofarabine) injection is a purine nucleoside metabolic inhibitorindicated for the treatment of pediatric patients 1 to 21 years old with relapsedor refractory acute lymphoblastic leukemia after at least two prior regimens.This indication is based upon response rate. There are no trials verifying animprovement in disease-related symptoms or increased survival with Clolar.(1) DrugBank Targets: ¹⁶ 1. DNA polymerase alpha catalytic subunit;2. Ribonucleoside-diphosphate reductase large subunit;3. DNA Mechanism of Action: ¹⁸ Target: ribonucleotide reductase Action: inhibitor FDA: Clofarabine is sequentially metabolized intracellularly to the 5â-monophosphate metabolite bydeoxycytidine kinase and mono- and di-phospho-kinases to the active 5â-triphosphate metabolite.Clofarabine has affinity for the activating phosphorylating enzyme, deoxycytidine kinase, equalto or greater than that of the natural substrate, deoxycytidine. Clofarabine inhibits DNA synthesisby decreasing cellular deoxynucleotide triphosphate pools through an inhibitory action onribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair throughincorporation into the DNA chain by competitive inhibition of DNA polymerases. The affinity ofclofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosinetriphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNArepair by incorporation into the DNA chain during the repair process. Clofarabine 5â-triphosphate also disrupts the integrity of mitochondrial membrane, leading to the release of thepro-apoptotic mitochondrial proteins, cytochrome C and apoptosis-inducing factor, leading toprogrammed cell death.Clofarabine is cytotoxic to rapidly proliferating and quiescent cancer cell types in vitro.
4	Erwinaze ¹⁸ ⁴⁹	asparaginase Erwinia chrysanthemi	Eusa Pharma	November of 2011
FDA Label: Erwinaze Disease/s that Drug Treats:acute lymphoblastic leukemia Indications and Usage: ¹⁸ ERWINAZE (asparaginase Erwinia chrysanthemi) is an asparagine specificenzyme indicated as a component of a multi-agent chemotherapeutic regimenfor the treatment of patients with acute lymphoblastic leukemia (ALL) whohave developed hypersensitivity to E. coli-derived asparaginase. (1) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: deamidation of asparagine to aspartic acid and ammonia Action: catalyzer FDA: Asparaginase Erwinia chrysanthemi catalyzes the deamidation of asparagine to aspartic acid and ammonia, resultingin a reduction in circulating levels of asparagine. The mechanism of action of ERWINAZE is thought to be based onthe inability of leukemic cells to synthesize asparagine due to lack of asparagine synthetase activity, resulting incytotoxicity specific for leukemic cells that depend on an exogenous source of amino acid asparagine for theirprotein metabolism and survival.
5	Iclusig ¹⁸ ⁴⁹	PONATINIB HYDROCHLORIDE	Ariad Pharmaceuticals	December 2012
FDA Label: Iclusig Disease/s that Drug Treats:chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia Indications and Usage: ¹⁸ Iclusig is a kinase inhibitor indicated for the: Treatment of adult patients with T315I-positive chronic myeloidleukemia (chronic phase, accelerated phase, or blast phase) or T315IpositivePhiladelphia chromosome positive acute lymphoblasticleukemia (Ph+ ALL). Treatment of adult patients with chronic phase, accelerated phase, orblast phase chronic myeloid leukemia or Ph+ ALL for whom no othertyrosine kinase inhibitor (TKI) therapy is indicated. (1)These indications are based upon response rate. There are no trials verifying animprovement in disease-related symptoms or increased survival with Iclusig. DrugBank Targets: ¹⁶ 1. Tyrosine-protein kinase ABL1;2. Breakpoint cluster region protein;3. Mast/stem cell growth factor receptor Kit;4. Proto-oncogene tyrosine-protein kinase receptor Ret;5. Angiopoietin-1 receptor;6. Receptor-type tyrosine-protein kinase FLT3;7. Fibroblast growth factor receptor 1;8. Fibroblast growth factor receptor 2;9. Fibroblast growth factor receptor 3;10. Fibroblast growth factor receptor 4;11. Tyrosine-protein kinase Lck;12. Proto-oncogene tyrosine-protein kinase Src;13. Tyrosine-protein kinase Lyn;14. Vascular endothelial growth factor receptor 2;15. Platelet-derived growth factor receptor alpha Mechanism of Action: ¹⁸ Target: tyrosine kinase activity of ABL and T315I mutant ABL Action: inhibitor FDA: Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL withIC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRCfamilies of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native ormutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native orT315I mutant BCR-ABL when compared to controls.
6	Marqibo ¹⁸ ⁴⁹	VINCRISTINE SULFATE	Talon Therapeutics	August 2012
FDA Label: Marqibo Disease/s that Drug Treats:Ph- acute lymphoblastic leukemia Indications and Usage: ¹⁸ Marqibo is a vinca alkaloid indicated for the treatment of adult patients withPhiladelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)in second or greater relapse or whose disease has progressed following two ormore anti-leukemia therapies. This indication is based on overall responserate. Clinical benefit such as improvement in overall survival has not beenverified (1.1). DrugBank Targets: ¹⁶ 1. Tubulin beta chain;2. Tubulin alpha-4A chain Mechanism of Action: ¹⁸ Target: tubulin Action: alters polymerization equilibrium FDA: Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate.Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting inaltered microtubule structure and function. Non-liposomal vincristine sulfate stabilizes the spindle apparatus,preventing chromosome segregation, triggering metaphase arrest and inhibition of mitosis.
7	Sprycel ¹⁸ ⁴⁹	DASATINIB	Bristol-Myers Squibb	June 2006
FDA Label: Sprycel Disease/s that Drug Treats:Chronic Myeloid Leukemia Indications and Usage: ¹⁸ SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+)chronic myeloid leukemia (CML) in chronic phase. (1, 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib. (1,14) adults with Philadelphia chromosome-positive acute lymphoblasticleukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14) DrugBank Targets: ¹⁶ 1. Tyrosine-protein kinase ABL1;2. Proto-oncogene tyrosine-protein kinase Src;3. Ephrin type-A receptor 2;4. Tyrosine-protein kinase Lck;5. Tyrosine-protein kinase Yes;6. Mast/stem cell growth factor receptor Kit;7. Platelet-derived growth factor receptor beta;8. Signal transducer and activator of transcription 5B;9. Abelson tyrosine-protein kinase 2;10. Tyrosine-protein kinase Fyn Mechanism of Action: ¹⁸ Target: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRÎ² kinases Action: inhibitor FDA: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRÎ². Based on modeling studies, dasatinib ispredicted to bind to multiple conformations of the ABL kinase.In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylatesensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia(CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under theconditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABLkinase domain mutations, activation of alternate signaling pathways involving the SRCfamily kinases (LYN, HCK), and multi-drug resistance gene overexpression.

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 619)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dasatinib

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

302962-49-8

3062316

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-02-2

5743

Methotrexate

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

1959-05-2, 59-05-2

126941

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

53-03-2

5865

Cytarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

147-94-4

6253

Daunorubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

20830-81-3

30323

Idarubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

58957-92-9

42890

Vincristine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

2068-78-2, 57-22-7

5978

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-18-0, 6055-19-2

2907

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

135968-09-1

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

83-43-2

6741

Prednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

50-24-8

5755

rituximab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

174722-31-7

10201696

Doxorubicin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

23214-92-8

31703

Pegaspargase

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

130167-69-0

Cladribine

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

4291-63-8

20279

Etoposide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

33419-42-0

36462

Fludarabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

21679-14-1, 75607-67-9

30751

Teniposide

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

29767-20-2

34698

Thioguanine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

154-42-7

2723601

Vindesine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

59917-39-4, 53643-48-4

40839

Ifosfamide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

3778-73-2

3690

Hydrocortisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

50-23-7

5754

Mitoxantrone

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

65271-80-9

4212

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Thiotepa

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

52-24-4

5453

Busulfan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

55-98-1

2478

Micafungin

Approved, Investigational

Phase 4,Phase 2

235114-32-6

3081921 477468

Posaconazole

Approved, Investigational, Vet_approved

Phase 4,Not Applicable

171228-49-2

147912

Dopamine

Approved

Phase 4,Not Applicable

51-61-6, 62-31-7

681

Methylphenidate

Approved, Investigational

Phase 4,Not Applicable

113-45-1

4158

Oprelvekin

Approved, Investigational

Phase 4

145941-26-0

Menthol

Approved

Phase 4,Not Applicable

2216-51-5

16666

Amphotericin B

Approved, Investigational

Phase 4,Phase 3,Phase 2

1397-89-3

14956 5280965

Nicotine

Approved

Phase 4

54-11-5

942 89594

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

59-30-3

6037

leucovorin

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

58-05-9

143 6006

Ergocalciferol

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2

50-14-6

5280793

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3,Phase 2

1406-16-2

Vitamin D3

Approved, Nutraceutical

Phase 4

67-97-0

6221 5280795

Doxil

Approved June 1999

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

31703

Butyric Acid

Experimental, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

107-92-6

264

Treosulfan

Investigational

Phase 4,Phase 3,Phase 2,Phase 1

299-75-2

9296

Lactitol

Investigational

Phase 4,Phase 2,Phase 1

585-86-4

3871

Antiemetics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Anti-Inflammatory Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antimetabolites

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antimetabolites, Antineoplastic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antineoplastic Agents, Hormonal

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1771)

#	Name	Status	NCT ID	Phase	Drugs
1	Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients	Unknown status	NCT02690922	Phase 4	Dasatinib;prednisone;dexamethasone;methotrexate
2	Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia	Unknown status	NCT01990807	Phase 4	Idarubicin(IDA)
3	German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Unknown status	NCT00198978	Phase 4	Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
4	Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003	Unknown status	NCT00222612	Phase 4	Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
5	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)	Unknown status	NCT00198991	Phase 4	Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
6	Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses	Unknown status	NCT00192673	Phase 4	PEG-asparaginase
7	HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL	Unknown status	NCT01873807	Phase 4	IDA;CTX;VP-16
8	Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults	Unknown status	NCT00797810	Phase 4	Rituximab
9	Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission	Unknown status	NCT01901666	Phase 4	Growth Hormone
10	Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia	Completed	NCT00411541	Phase 4	vincristine;dexamethasone
11	Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia	Completed	NCT01358253	Phase 4	Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
12	LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia	Completed	NCT00526409	Phase 4	Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
13	PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia	Completed	NCT00494897	Phase 4	Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
14	Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia	Completed	NCT00199095	Phase 4	Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
15	LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive	Completed	NCT00526305	Phase 4	Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
16	ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia	Completed	NCT00114348	Phase 4
17	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)	Completed	NCT00199069	Phase 4	Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
18	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)	Completed	NCT00199056	Phase 4	Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
19	Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab	Completed	NCT00199004	Phase 4	Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
20	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Completed	NCT01200355	Phase 4	micafungin;posaconazole
21	Learning Impairments Among Survivors of Childhood Cancer	Completed	NCT00576472	Phase 4	Methylphenidate
22	LAL-BR/2001: Study Treatment to Low Risk ALL	Completed	NCT00526175	Phase 4	Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
23	Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL	Completed	NCT02314273	Phase 4	rhIL-11
24	The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents	Completed	NCT02953730	Phase 4	PEG-rhG-CSF
25	Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults	Completed	NCT00199082	Phase 4	Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
26	German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults	Completed	NCT00199017	Phase 4	Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
27	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
28	Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase	Completed	NCT01061177	Phase 4	Nilotinib
29	Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia	Recruiting	NCT02618109	Phase 4
30	Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)	Recruiting	NCT01366898	Phase 4	Dexamethasona, Idarubicine, ARA-C, Methotrexate
31	The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia	Recruiting	NCT00846703	Phase 4	6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
32	Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study	Recruiting	NCT02894645	Phase 4	Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
33	Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE	Recruiting	NCT01491763	Phase 4	Imatinib
34	Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid	Recruiting	NCT01906671	Phase 4	Xaluprine;Puri-Nethol
35	PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years	Recruiting	NCT01358201	Phase 4	vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
36	Vaccinating Children After Chemotherapy	Recruiting	NCT02447718	Phase 4
37	ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)	Recruiting	NCT02670564	Phase 4
38	Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia	Recruiting	NCT02036489	Phase 4	Vincristine;Daunorubicin;Prednisone;L-asparaginase;Ciclophosphamide;Metotrexate;ARA-C;Hidrocortisone;Mercaptopurine;VP-16;Dexametasone
39	ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors	Recruiting	NCT02938741	Phase 4	Anti－human Thymoglobulin;Placebo
40	A Clinical Trial of Decitabine in Relapse and Refractory T-lymphoblastic Lymphoma	Recruiting	NCT03558412	Phase 4	Decitabine
41	Treatment of High Risk Adult Acute Lymphoblastic Leukemia	Active, not recruiting	NCT00853008	Phase 4	Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
42	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Not yet recruiting	NCT02933333	Phase 4
43	A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT	Not yet recruiting	NCT03176849	Phase 4
44	ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia	Terminated	NCT00386997	Phase 4	liposomal amphotericin B (AmBisome®)
45	Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL	Terminated	NCT00299234	Phase 4	Atomoxetine
46	Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia	Unknown status	NCT02072785	Phase 3	Vincristine Sulfate Liposome;Vincristine Sulfate
47	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Unknown status	NCT00103285	Phase 3	doxorubicin hydrochloride;cytarabine;dexamethasone;pegaspargase;methotrexate;leucovorin calcium;mercaptopurine;cyclophosphamide;thioguanine;vincristine sulfate
48	Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt	Unknown status	NCT00199108	Phase 2, Phase 3	Depocyt;Dexamethasone
49	High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)	Unknown status	NCT00131027	Phase 3	Cyclophosphamide;Daunorubicin;Vincristine;Prednisolone;L-asparaginase;Cytarabine;Etoposide;Dexamethasone;Methotrexate;Mercaptopurine;Doxorubicin;Methotrexate
50	Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia	Unknown status	NCT00003437	Phase 3	asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;mercaptopurine;methotrexate;pegaspargase;prednisolone;thioguanine;vincristine sulfate

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

asparaginase

cyclophosphamide

idarubicin

idarubicin hydrochloride

ifosfamide

mercaptopurine

pegaspargase

sargramostim

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Leukemia, Acute Lymphoblastic:

	Hemacord
	NiCord
	Umbilical cord-derived hematopoietic stem cells for treatment of acute lymphoblastic leukemia

Embryonic/Adult Cultured Cells Related to Leukemia, Acute Lymphoblastic:

	Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244
	Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
	Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 17968329

Sources

Genetic Tests for Leukemia, Acute Lymphoblastic

Genetic tests related to Leukemia, Acute Lymphoblastic:

#	Genetic test	Affiliating Genes
1	Leukemia, Acute Lymphoblastic, Susceptibility to ²⁹
2	Acute Lymphoblastic Leukemia ²⁹

Sources

Anatomical Context for Leukemia, Acute Lymphoblastic

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

⁴¹

T Cells, B Cells, Bone, Bone Marrow, Myeloid, Liver, Kidney

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:

#	Tissue Anatomical CompartmentCell	Relevance
1	Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells	Potential therapeutic candidate
2	Blood Peripheral Blood Mature B-Cells	Affected by disease
3	Blood Hematopoietic Bone Marrow Small Pre B-Cells	Affected by disease

Sources

Publications for Leukemia, Acute Lymphoblastic

Articles related to Leukemia, Acute Lymphoblastic:

(show top 50) (show all 3627)

#	Title	Authors	Year
1	Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia. ( 28853218 )	Liang D.C....Shih L.Y.	2018
2	Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. ( 29360413 )	Sakamoto K....Horibe K.	2018
3	Acute Lymphoblastic Leukemia Presenting as Fanconi Syndrome. ( 29515412 )	Yoshida T....Suzuki H.	2018
4	Immunosuppressive monocytes (CD14<sup>+</sup>/HLA-DR<sup>low/-</sup>) increase in childhood precursor B-cell acute lymphoblastic leukemia after induction chemotherapy. ( 29429058 )	Lima D.S....Matos D.M.	2018
5	Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism. ( 29977016 )	Studd J.B....Houlston R.S.	2018
6	The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway. ( 29330049 )	Fu Y....Chen C.	2018
7	Anti-E Detected in a 7-Month-Old Infant with Acute Lymphoblastic Leukemia after Transfusion. ( 29945333 )	Kumeta M....Saito N.	2018
8	Long non-coding RNA PAX8-AS1 polymorphisms increase the risk of childhood acute lymphoblastic leukemia. ( 29435279 )	Bahari G....Taheri M.	2018
9	Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. ( 29954814 )	Stein A.S....Topp M.S.	2018
10	<i>PDGFRB</i> mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. ( 29434033 )	Zhang Y....Liu X.	2018
11	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. ( 29090524 )	Rau R.E....Hunger S.P.	2018
12	Erratum: Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]. ( 29443320 )		2018
13	Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia. ( 29200162 )	Valliyammai N....Rajkumar T.	2018
14	Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia. ( 29954929 )	Ganzel C....Rowe J.M.	2018
15	A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy. ( 29434963 )	Cai H....Xiao M.	2018
16	Combination of Blinatumomab and Vincristine Sulfate Liposome Injection for Treatment of Relapsed Philadelphia Chromosome Positive B-cell Acute Lymphoblastic Leukemia. ( 29953129 )	McCusker M.G....Duong V.H.	2018
17	Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia. ( 29967774 )	Jiang Q....Zheng H.	2018
18	Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate. ( 29424258 )	ZajA8c-SpychaA8a O....Wachowiak J.	2018
19	Extranodal histiocytic sarcoma in a child with acute lymphoblastic leukemia: Cytomorphological features of a rare entity with brief review of literature. ( 29676378 )	Pani K.C....Agrawal V.	2018
20	Successful Combination Therapy of Liposomal Amphotericin B and Caspofungin for Disseminated Fusariosis in a Pediatric Patient with Acute Lymphoblastic Leukemia. ( 29438132 )	Uemura S....Kosaka Y.	2018
21	Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels. ( 29278703 )	Miyashita K....Hara T.	2018
22	Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia &amp; lymphoma study. ( 29728694 )	Sun W....Whitlock J.A.	2018
23	Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. ( 29047158 )	Abaza Y....Ravandi F.	2018
24	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. ( 29949919 )	Evangelisti C....Martelli A.M.	2018
25	Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). ( 29437555 )	Yun S....Pinilla-Ibarz J.	2018
26	A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing. ( 29954933 )	Verboom K....Durinck K.	2018
27	Living on a farm, contact with farm animals and pets, and childhood acute lymphoblastic leukemia: pooled and meta-analyses from the Childhood Leukemia International Consortium. ( 29663688 )	Orsi L....Clavel J.	2018
28	Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. ( 29970035 )	SA!gi J.C....Semsei A.8.F.	2018
29	Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium. ( 29761423 )	Petridou E.T....Skalkidou A.	2018
30	Recent Developments in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia. ( 29442287 )	Orellana-Noia V.M....Douvas M.G.	2018
31	Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia. ( 29967378 )	Lundin-StrAPm K.B....Johansson B.	2018
32	Nephrogenic diabetes insipidus in initial stage of acute lymphoblastic leukemia and relapse after haploidentical hematopoietic stem-cell transplantation: A case report. ( 29901649 )	Li D....Feng S.	2018
33	A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia. ( 29424254 )	Derrieux C....Fouillard L.	2018
34	Brain morphology and information processing at the completion of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. ( 29969366 )	Darling S....Seal M.	2018
35	Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity. ( 29231963 )	Marriott C.J.C....Barr R.D.	2018
36	A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia. ( 29922939 )	Oosterom N....Pluijm S.M.F.	2018
37	Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults. ( 29418064 )	McNeer J.L....Bleyer A.	2018
38	Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. ( 29449437 )	Sinclair P.B....Harrison C.J.	2018
39	Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. ( 29943905 )	Mogensen S.S....Frandsen T.L.	2018
40	Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. ( 29450465 )	Siegel S.E....Bleyer A.	2018
41	Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation canA improve clinical outcomes. ( 29942002 )	Tang S....Tang X.	2018
42	Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia. ( 29948644 )	Hefazi M....Litzow M.R.	2018
43	Acute lymphoblastic leukemia in a male with Simpson-Golabi-Behmel syndrome. ( 29737011 )	Minatogawa M....Kurosawa K.	2018
44	Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. ( 28971501 )	El Fakih R....Kantarjian H.	2018
45	In vitro combinatorial anti-proliferative and immunosuppressive effects of Brucea javanica extract with CX-4945 and imatinib in human T-cell acute lymphoblastic leukemia cells. ( 29966986 )	Jung J.I....Kim J.	2018
46	Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. ( 29441205 )	Xie V....Bendall L.J.	2018
47	A strategy for the clinical remission of acute lymphoblastic leukemia elicited by treatment of I^-thalassemia major: A case report. ( 29435306 )	Palomo-Colli M.A....CA^rdova-Hurtado L.P.	2018
48	A rare variant of t(17;19) in a case of Philadelphia positive adult acute lymphoblastic leukemia presenting with disseminated intravascular coagulation. ( 29662872 )	Safavi M....Lotfi M.	2018
49	Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia. ( 29966470 )	Kathiravan M....Naseem S.	2018
50	Comparison of target volume and clinical effects of four radiotherapy plans for acute lymphoblastic leukemia prior to hematopoietic stem cell transplantation. ( 29956788 )	Lin Y....Li G.	2018

Sources

Genes for Leukemia, Acute Lymphoblastic

Genes related to Leukemia, Acute Lymphoblastic (10 elite genes):

(show top 50) (show all 51)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	ETV6	ETS Variant 6	Protein Coding	427.12	Pathogenic ⁶ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12764377 16490598 7795247 (more) 9204978 9326218 11468150 9169030 7492786 11960347 11960348 19594616 7761424 8704231 9028935 9087565 9454771 9864173 12626745 16213362 11801311 9305598 9060558 8605354 16211447 19727243 9664088
2	FLT3	Fms Related Tyrosine Kinase 3	Protein Coding	426.48	Pathogenic ⁶ Novoseek inferred ⁵⁵ GeneCards inferred via : Variants (show sections)	16234090 18024407 19968062 (more) 12176867 15956279 17156841 7535088 8946930 12400596 15604885 17205058 17584026 10720156 8641368 19085113 14604973 16594743 14504097 17708788 18760705 17881645 15044257 15583855 16116483 17942916 1384791 8637232 9324277
3	GNB1	G Protein Subunit Beta 1	Protein Coding	400	Pathogenic ⁶
4	ACTB	Actin Beta	Protein Coding	400	Pathogenic ⁶
5	MIR203A	MicroRNA 203a We report a fragile chromosomal region lost in specific hematopoietic malignancies. This 7 Mb region encodes about 12% of all genomic microRNAs, including miR-203. This microRNA is additionally hypermethylated in several hematopoietic tumors, including chronic myelogenous leukemias and some acute lymphoblastic leukemias. A putative miR-203 target, ABL1, is specifically activated in these hematopoietic malignancies in some cases as a BCR-ABL1 fusion protein (Philadelphia chromosome). Re-expression of miR-203 reduces ABL1 and BCR-ABL1 fusion protein levels and inhibits tumor cell proliferation in an ABL1-dependent manner. Thus, miR-203 functions as a tumor suppressor, and re-expression of this microRNA might have therapeutic benefits in specific hematopoietic malignancies.	RNA Gene	350	Causal ⁴⁷	18538733
6	MIR155	MicroRNA 155 Transgenic mice with overexpression of miR155 develop a lymphoproliferative disease resembling the human diseases, thus strongly suggesting that miR-155 is directly implicated in the initiation and or progression of these diseases.	RNA Gene	350	Causal ⁴⁷	16641092
7	MIR152	MicroRNA 152 It was showed that the silenced status of miR-152 has impact on the survival of t(4;11)-positive infant ALL patients. This silenced status can be reversed by Zebularine. Altogether, this study indicates that although miRNAs are small in size, they have major implications in t(4;11)-positive infant ALL. This emphasizes the need for further investigation of de-methylating agents, like Zebularine, to improve the treatment of these young patients with leukemia. DNMT1 is putative target for mir-152.	RNA Gene	350	Causal ⁴⁷	21116279
8	PAX5	Paired Box 5	Protein Coding	334.83	Causative variation ⁷⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Disorders Variants (show sections)	17179230 19587702 10905058 (more) 18293359
9	ALL2	Leukemia, Acute Lymphoblastic, Susceptibility To, 2	Genetic Locus	58.61	MalaCards inferred ⁵⁷ GeneCards inferred via : Gene name (show sections)
10	MIR221	MicroRNA 221 Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
11	MIR223	MicroRNA 223 miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML.	RNA Gene	50	Unspecified ⁴⁷	18056805
12	MIR22	MicroRNA 22 MIR22 is an extronic miRNA and resides in the second exon of the non-coding transcript MGC14376. Upregulation of MIR22 transcription was found in both NALM-6 cells and primary human ALL malignant cells treated with TSA. Whereas a CpG island was identified within the promoter element of MIR22, no promoter DNA methylation was detected in these cells. In contrast, accumulation of the repressive histone marker H3K27 trimethylation (H3K27triM) was indentified around the transcriptional start point of the gene, which was reduced by TSA treatment. Thus, accumulation of H3K27triM independent of promoter DNA methylation may be a novel epigenetic mechanism for MIR22 silencing in ALL.	RNA Gene	50	Unspecified ⁴⁷	19807731
13	MIR222	MicroRNA 222 Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
14	MIR199B	MicroRNA 199b Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
15	MIR23B	MicroRNA 23b Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
16	MIR27A	MicroRNA 27a Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
17	MIR21	MicroRNA 21 Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
18	ALL1	Leukemia, Acute Lymphocytic, Susceptibility To, 1	Genetic Locus	50	Susceptibility factor ⁵⁷
19	MIR210	MicroRNA 210 Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
20	MIRLET7C	MicroRNA Let-7c Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
21	MIR128-2	MicroRNA 128-2 miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML.	RNA Gene	50	Unspecified ⁴⁷	18056805
22	MIR130A	MicroRNA 130a Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
23	MIR130B	MicroRNA 130b Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
24	MIR196B	MicroRNA 196b Most remarkably, miR-708 was 250-up to 6500-fold higher expressed in 57 TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid and B-other cases than in 20 MLL-rearranged and 15 T-ALL cases (0.0001	RNA Gene	50	Unspecified ⁴⁷	18923441
25	MIR128-1	MicroRNA 128-1 miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML.	RNA Gene	50	Unspecified ⁴⁷	18056805
26	MIR125A	MicroRNA 125a Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
27	MIRLET7E	MicroRNA Let-7e Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
28	MIR708	MicroRNA 708 Most remarkably, miR-708 was 250-up to 6500-fold higher expressed in 57 TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid and B-other cases than in 20 MLL-rearranged and 15 T-ALL cases (0.0001	RNA Gene	50	Unspecified ⁴⁷	18923441
29	MIR451A	MicroRNA 451a Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
30	MIR23A	MicroRNA 23a Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
31	MIRLET7B	MicroRNA Let-7b miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly downregulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML.	RNA Gene	50	Unspecified ⁴⁷	18056805
32	MIR335	MicroRNA 335 Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
33	MIR27B	MicroRNA 27b Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
34	MIR424	MicroRNA 424 Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
35	NBN	Nibrin	Protein Coding	44.67	Risk factor ⁶ Novoseek inferred ⁵⁵ GeneCards inferred via : Variants (show sections)	11325820 15338273 15338273
36	SETD2	SET Domain Containing 2	Protein Coding	28.9	GeneCards inferred via : Disorders Variants (show sections)
37	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	24	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17364061 7694687 15543372 (more) 1283551 1364132 7643452 9613976 19467705 19672972 9671132 18310528 12851703 12410571 7914748 7906380 16206189 16849280 12860010 11999562 9886170 7622426 15766280 10897123 7905944 1974821 1972761 10920991 8528050 12969965 9490695 11323101 20423567
38	PICALM	Phosphatidylinositol Binding Clathrin Assembly Protein	Protein Coding	22.42	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10637482
39	CDKN2C	Cyclin Dependent Kinase Inhibitor 2C	Protein Coding	21.8	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	8637234 7606004 14513284 (more) 8443393 12496407
40	KMT2A	Lysine Methyltransferase 2A	Protein Coding	20.75	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	7579356 10588740 19229974 (more) 17690691 11731795 15618957 10825008 15755504 18024407 19144982 15297313 12203795 16478880 15751040 14712291 8298125 8025282 8824725 10738298 15323147 16307022 7655016 15704140 12885948 11493704 10394590 9844603 18932267 17854671 16123216 10602437 10557043 8639906 8558942 7845017 8389614 19893343 20175452 19262598 14580777 14527352 12229886 9824651 9365243 9331569 9168451 8219184 19212338 19665068 16024815 15269783 18794461 17905612 15631201 15221006 14604973 9529125 9389682 8527389 7885037 16211447 15334550 12941810 12743608 12618768 11196198 10457404 16001262 16158826 9844825 9808573 7549829 18448165 16772125 9372085 16158928 12800152 10865968 10374870 16019540 12782787 8620491
41	RUNX1	Runt Related Transcription Factor 1	Protein Coding	19.39	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	12550760 12646943 11587363 (more) 12145988 11960347 16702559 7761424 9864173 11023523 16213362 11801311 17243167 16584381 20306249 10455134 9664088 7780155 12874780 10825008 9332479 19594616 11960348 7492786 11579464
42	TRD	T Cell Receptor Delta Locus	Protein Coding	19.38	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	12774926 10025893 1328776 (more) 7606000 10463485 1832201 9407937
43	CD19	CD19 Molecule	Protein Coding	19.08	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	7517719
44	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	19.08	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	8242587 8632666 11801308 (more) 15964830 2160631 1932752 9490692 15265366 9790503 20082857 15621812 16213359
44	ABL1::MIR203A ⁴⁷	MIR203A Macro RNA (hsa-miR-203) targets ABL1
45	TPMT	Thiopurine S-Methyltransferase	Protein Coding	18.95	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	1960624 16886902 18987654 (more) 20021291 11037857 18801934 7703493 8861653 10580024 12021625 17015055 17617792 19057372 12949626 16401827 11681411 9763570 10491537 12142782 15543619 15943548 19663675
46	BCR	BCR, RhoGEF And GTPase Activating Protein	Protein Coding	18.94	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	2145450 1705008 8426467 (more) 11369654 14614449 1993310 1545509 1932752 10640143 12537978 8251913 16767900 16213359 9874796 8467803 16297978 12970766 8242587 9349495 9544977 17496935 19608682 2160631
47	MME	Membrane Metalloendopeptidase	Protein Coding	18.84	Novoseek inferred ⁵⁵ GeneCards inferred via : Novoseek inferred (show sections)	1535484 2348236 2118055 (more) 1708483 1717072 1531755 1991995 1827572 8217197 14739539 8392520 1836104 2166607 20051780 14531802 8739278 8030658 2375683 19190692 8556402 7895527 8302714 1359807 2137547 18032951 14517614 9856287 9003829 2174414 16540734 11950913 9748792 8302012 8420302 2137556 1532880 1533518 8808423 11853934
48	DNTT	DNA Nucleotidylexotransferase	Protein Coding	14.16	Novoseek inferred ⁵⁵	7556527 9343323 7723388 (more) 16454553 16918360 1338518 8819075 2278964 10629138 7937725 1836104 8683996 9110287 1996546 8366299
49	IGH	Immunoglobulin Heavy Locus	Protein Coding	9.83	Novoseek inferred ⁵⁵	19324994 1850055 8187567 (more) 10485272 10891460 2114388 10942239 16329531 7914873 8350631 8630417 8695809 15262434
50	AFF1	AF4/FMR2 Family Member 1	Protein Coding	9.76	Novoseek inferred ⁵⁵	11719380 11493704 12433702 (more) 15221006 15631201 8219184 8555498 9365243 15269783

Sources

Variations for Leukemia, Acute Lymphoblastic

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

⁷⁵

#	Symbol	AA change	Variation ID	SNP ID
1	PAX5	p.Gly183Ser	VAR_070682	rs398123063

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

⁶

(show all 21)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	NBN	NM_002485.4(NBN): c.511A> G (p.Ile171Val)	single nucleotide variant	risk factor	rs61754966	GRCh37	Chromosome 8, 90990521: 90990521
2	NBN	NM_002485.4(NBN): c.511A> G (p.Ile171Val)	single nucleotide variant	risk factor	rs61754966	GRCh38	Chromosome 8, 89978293: 89978293
3	FLT3	NM_004119.2(FLT3): c.2504A> T (p.Asp835Val)	single nucleotide variant	Pathogenic	rs121909646	GRCh37	Chromosome 13, 28592641: 28592641
4	FLT3	NM_004119.2(FLT3): c.2504A> T (p.Asp835Val)	single nucleotide variant	Pathogenic	rs121909646	GRCh38	Chromosome 13, 28018504: 28018504
5	FLT3	NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr)	single nucleotide variant	Pathogenic	rs121913488	GRCh37	Chromosome 13, 28592642: 28592642
6	FLT3	NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr)	single nucleotide variant	Pathogenic	rs121913488	GRCh38	Chromosome 13, 28018505: 28018505
7	FLT3	NM_004119.2(FLT3): c.1777_1779delGAT (p.Asp593del)	deletion	Pathogenic	rs587776834	GRCh38	Chromosome 13, 28034140: 28034142
8	FLT3	NM_004119.2(FLT3): c.1777_1779delGAT (p.Asp593del)	deletion	Pathogenic	rs587776834	GRCh37	Chromosome 13, 28608277: 28608279
9	NBN	NM_002485.4(NBN): c.2140C> T (p.Arg714Ter)	single nucleotide variant	Pathogenic/Likely pathogenic	rs730881864	GRCh38	Chromosome 8, 89943297: 89943297
10	NBN	NM_002485.4(NBN): c.2140C> T (p.Arg714Ter)	single nucleotide variant	Pathogenic/Likely pathogenic	rs730881864	GRCh37	Chromosome 8, 90955525: 90955525
11	ETV6	NM_001987.4(ETV6): c.1153-5_1153-1delAACAG	deletion	Pathogenic	rs786205154	GRCh37	Chromosome 12, 12038855: 12038859
12	ETV6	NM_001987.4(ETV6): c.1153-5_1153-1delAACAG	deletion	Pathogenic	rs786205154	GRCh38	Chromosome 12, 11885921: 11885925
13	ETV6	NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro)	single nucleotide variant	Pathogenic	rs786205155	GRCh37	Chromosome 12, 12037415: 12037415
14	ETV6	NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro)	single nucleotide variant	Pathogenic	rs786205155	GRCh38	Chromosome 12, 11884481: 11884481
15	ACTB	NP_001092.1(ACTB): p.Val209Leu	protein only	Pathogenic
16	GNB1	NM_002074.4(GNB1): c.239T> A (p.Ile80Asn)	single nucleotide variant	Pathogenic	rs752746786	GRCh37	Chromosome 1, 1737942: 1737942
17	GNB1	NM_002074.4(GNB1): c.239T> A (p.Ile80Asn)	single nucleotide variant	Pathogenic	rs752746786	GRCh38	Chromosome 1, 1806503: 1806503
18	GNB1	NM_002074.4(GNB1): c.227A> G (p.Asp76Gly)	single nucleotide variant	Pathogenic	rs869312821	GRCh38	Chromosome 1, 1806515: 1806515
19	GNB1	NM_002074.4(GNB1): c.227A> G (p.Asp76Gly)	single nucleotide variant	Pathogenic	rs869312821	GRCh37	Chromosome 1, 1737954: 1737954
20	NBN	NM_002485.4(NBN): c.156_157delTT (p.Ser53Cysfs)	deletion	Pathogenic/Likely pathogenic	rs767454740	GRCh38	Chromosome 8, 89982736: 89982737
21	NBN	NM_002485.4(NBN): c.156_157delTT (p.Ser53Cysfs)	deletion	Pathogenic/Likely pathogenic	rs767454740	GRCh37	Chromosome 8, 90994964: 90994965

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

⁷ (show top 50) (show all 2943)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	13316	1	1	117600000	Loss		Acute lymphoblastic leukemia
2	13371	17	1	22200000	Deletion	TP53	Acute lymphoblastic leukemia
3	13410	1	1	2300000	Copy number		Acute lymphoblastic leukemia
4	13773	1	1	35400000	Duplication		Acute lymphoblastic leukemia
5	13788	1	1	40300000	Duplication		Acute lymphoblastic leukemia
6	13790	1	1	46500000	Gain		Acute lymphoblastic leukemia
7	13836	12	10000000	12600000	Deletion	ETV6	Acute lymphoblastic leukemia
8	13906	1	100818677	103024856	Loss	DPH5	Acute lymphoblastic leukemia
9	13907	1	100818677	103024856	Loss	EXTL2	Acute lymphoblastic leukemia
10	13908	1	100818677	103024856	Loss	OLFM3	Acute lymphoblastic leukemia
11	13909	1	100818677	103024856	Loss	S1PR1	Acute lymphoblastic leukemia
12	13910	1	100818677	103024856	Loss	SLC30A7	Acute lymphoblastic leukemia
13	13911	1	100818677	103024856	Loss	VCAM1	Acute lymphoblastic leukemia
14	13991	1	102370195	102561809	Deletion		Acute lymphoblastic leukemia
15	14292	1	106673274	107678605	Loss	NTNG1	Acute lymphoblastic leukemia
16	14293	1	106673274	107678605	Loss	PRMT6	Acute lymphoblastic leukemia
17	14369	1	107716342	144004701	Loss	ADAM30	Acute lymphoblastic leukemia
18	14370	1	107716342	144004701	Loss	ADORA3	Acute lymphoblastic leukemia
19	14371	1	107716342	144004701	Loss	AFARP1	Acute lymphoblastic leukemia
20	14372	1	107716342	144004701	Loss	AHCYL1	Acute lymphoblastic leukemia
21	14373	1	107716342	144004701	Loss	AKNAD1	Acute lymphoblastic leukemia
22	14374	1	107716342	144004701	Loss	ALX3	Acute lymphoblastic leukemia
23	14375	1	107716342	144004701	Loss	AMIGO1	Acute lymphoblastic leukemia
24	14376	1	107716342	144004701	Loss	AMPD1	Acute lymphoblastic leukemia
25	14377	1	107716342	144004701	Loss	AMPD2	Acute lymphoblastic leukemia
26	14378	1	107716342	144004701	Loss	AP4B1	Acute lymphoblastic leukemia
27	14379	1	107716342	144004701	Loss	ATP1A1	Acute lymphoblastic leukemia
28	14380	1	107716342	144004701	Loss	ATP5F1	Acute lymphoblastic leukemia
29	14381	1	107716342	144004701	Loss	ATXN7L2	Acute lymphoblastic leukemia
30	14382	1	107716342	144004701	Loss	BCAS2	Acute lymphoblastic leukemia
31	14383	1	107716342	144004701	Loss	BCL2L15	Acute lymphoblastic leukemia
32	14384	1	107716342	144004701	Loss	C1orf103	Acute lymphoblastic leukemia
33	14385	1	107716342	144004701	Loss	C1orf152	Acute lymphoblastic leukemia
34	14386	1	107716342	144004701	Loss	C1orf161	Acute lymphoblastic leukemia
35	14387	1	107716342	144004701	Loss	C1orf162	Acute lymphoblastic leukemia
36	14388	1	107716342	144004701	Loss	C1orf183	Acute lymphoblastic leukemia
37	15383	1	115048600	115061038	Copy number	NRAS	Acute lymphoblastic leukemia
38	15429	1	115400000	222100000	Gain		Acute lymphoblastic leukemia
39	15832	1	119869201	120436800	Loss	HMGCS2	Acute lymphoblastic leukemia
40	15833	1	119869201	120436800	Loss	NBPF7	Acute lymphoblastic leukemia
41	15834	1	119869201	120436800	Loss	NOTCH2	Acute lymphoblastic leukemia
42	15835	1	119869201	120436800	Loss	PHGDH	Acute lymphoblastic leukemia
43	15836	1	119869201	120436800	Loss	REG4	Acute lymphoblastic leukemia
44	15837	1	119869201	120436800	Loss	ZNF697	Acute lymphoblastic leukemia
45	15979	1	120700000	169100000	Loss	CREG1	Acute lymphoblastic leukemia
46	16426	1	124300000	247249719	Deletion		Acute lymphoblastic leukemia
47	16427	1	124300000	247249719	Duplication		Acute lymphoblastic leukemia
48	16474	1	125000000	249250621	Copy number		Acute lymphoblastic leukemia
49	16502	1	12600000	16100000	Deletion		Acute lymphoblastic leukemia
50	16592	1	128000000	185104377	Copy number		Acute lymphoblastic leukemia

Sources

Expression for Leukemia, Acute Lymphoblastic

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.

Sources

Pathways for Leukemia, Acute Lymphoblastic

Pathways related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	11.93	MIR203A MIR210 MIR221 MIR222
2	MicroRNAs in cancer ³⁷	11.88	MIR152 MIR155 MIR199B MIR203A MIR21 MIR210
3	miRNAs involved in DNA damage response ¹	11.13	MIR203A MIR210 MIR221 MIR222 MIR23B MIR27A
4	Cell Differentiation - Index ¹	10.91	MIR203A MIR221 MIR222
5	Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex ¹	10.66	ETV6 FLT3

Sources

GO Terms for Leukemia, Acute Lymphoblastic

Cellular components related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.44	ACTB MIR152 MIR155 MIR199B MIR21 MIR210

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

(show all 29)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of protein kinase B signaling	GO:0051897	9.84	MIR199B MIR21 MIR221 MIR222
2	positive regulation of angiogenesis	GO:0045766	9.82	MIR199B MIR21 MIR210
3	negative regulation of inflammatory response	GO:0050728	9.77	MIR155 MIR221 MIR222
4	positive regulation of inflammatory response	GO:0050729	9.76	MIR155 MIR21 MIR22
5	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.72	FLT3 MIR21 MIR221 MIR222 MIR27A
6	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.7	MIR21 MIR221 MIR222
7	negative regulation of cell migration involved in sprouting angiogenesis	GO:0090051	9.69	MIR155 MIR22 MIR221
8	positive regulation of vascular smooth muscle cell proliferation	GO:1904707	9.67	MIR21 MIR221 MIR222
9	positive regulation of cardiac muscle cell proliferation	GO:0060045	9.65	MIR199B MIR222 MIR23B
10	negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	GO:1903588	9.64	MIR155 MIR222
11	positive regulation of activated T cell proliferation	GO:0042104	9.63	MIR155 MIR21
12	positive regulation of cardiac muscle hypertrophy	GO:0010613	9.63	MIR155 MIR21
13	positive regulation of vascular endothelial cell proliferation	GO:1905564	9.62	MIR21 MIR27A
14	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.62	MIR21 MIR221
15	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.61	MIR21 MIR223
16	positive regulation of endothelial cell differentiation	GO:0045603	9.61	MIR199B MIR21
17	negative regulation of cytokine production involved in inflammatory response	GO:1900016	9.59	MIR221 MIR222
18	positive regulation of axon regeneration	GO:0048680	9.58	MIR221 MIR222
19	negative regulation by host of viral genome replication	GO:0044828	9.57

Leukemia, Acute Lymphoblastic

Aliases & Classifications for Leukemia, Acute Lymphoblastic

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Characteristics:

HPO:

Classifications:

External Ids:

Summaries for Leukemia, Acute Lymphoblastic

Related Diseases for Leukemia, Acute Lymphoblastic

Diseases in the Lymphoblastic Leukemia family:

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

Clinical features from OMIM:

Human phenotypes related to Leukemia, Acute Lymphoblastic:

UMLS symptoms related to Leukemia, Acute Lymphoblastic:

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

FDA approved drugs:

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cell-based therapeutics:

Genetic Tests for Leukemia, Acute Lymphoblastic

Genetic tests related to Leukemia, Acute Lymphoblastic:

Anatomical Context for Leukemia, Acute Lymphoblastic

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

Publications for Leukemia, Acute Lymphoblastic

Articles related to Leukemia, Acute Lymphoblastic:

Genes for Leukemia, Acute Lymphoblastic

Genes related to Leukemia, Acute Lymphoblastic (10 elite genes):

Variations for Leukemia, Acute Lymphoblastic

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

Expression for Leukemia, Acute Lymphoblastic

Pathways for Leukemia, Acute Lymphoblastic

Pathways related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

GO Terms for Leukemia, Acute Lymphoblastic

Cellular components related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :